Metsera, Inc.
Metsera, Inc. (MTSR) Stock Overview
Key statistics and deep links to earnings, valuation, revenue, dividends, and more.
FMP · MTSR · as of Jun 9, 2026
Key Statistics
Explore Metsera, Inc. Data
mtsr stock data · financialsFinancial Snapshot
Full FinancialsAnalyst Ratings & Price Target
Full ForecastTotal: 4 · Buy rate: 75.0%
The MTSR analyst consensus is Buy, based on ratings from 4 Wall Street analysts over the past 3 months. The average 12-month price target is $55.50, representing -21.28% downside from the current price of $70.50.
Competitors & Peers
mtsr competitorsMTSR
ABVX
ACLX
ARWR
AXSM
CRSPStock Performance
Full HistoryAbout Metsera, Inc.
Metsera, Inc. operates as a clinical-stage biotechnology firm, specializing in crafting both injectable and oral nutrient-stimulated hormone analog peptides. These therapeutic compounds are primarily …
what is metsera, inc. · mtsr stock overview · metsera, inc. company profile · who is metsera, inc. ceo · mtsr NASDAQ · metsera, inc. headquarters · metsera, inc. business segments
About Stock Overview & Key Data
Metsera, Inc. (MTSR) is a Healthcare company in the Biotechnology industry, listed on NASDAQ since Jan 31, 2025. As of the latest trading session, MTSR stock price is $70.50, with a market capitalization of $7.4B. The stock has returned +166.04% over the past 12 months and +166.04% year-to-date.
According to 4 Wall Street analysts, the consensus rating for Metsera, Inc. stock is Buy, with an average 12-month price target of $55.50. In fiscal year 2024, Metsera, Inc. reported revenue of — and net income of -$209.1M. For detailed data — including Metsera, Inc. revenue history, earnings, dividends, and PE ratio — use the tabs above.
Frequently Asked Questions
As of the latest trading session, Metsera, Inc. (MTSR) stock price is $70.50. The stock is traded on NASDAQ under the ticker symbol MTSR. The 52-week range is $12.30 – $83.86.